Cargando…

Do androgen deprivation and the biologically equivalent dose matter in low‐dose‐rate brachytherapy for intermediate‐risk prostate cancer?

The objective of this study was to investigate the impact of the biologically equivalent dose (BED) on treatment outcomes after iodine‐125 low‐dose‐rate brachytherapy (LDR‐BT) with or without supplemental external beam radiotherapy (EBRT) and androgen deprivation therapy (ADT) for intermediate‐risk...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tabata, Ryuji, Kimura, Takahiro, Kuruma, Hidetoshi, Sasaki, Hiroshi, Kido, Masahito, Miki, Kenta, Takahashi, Hiroyuki, Aoki, Manabu, Egawa, Shin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055153/ https://www.ncbi.nlm.nih.gov/pubmed/27456710 http://dx.doi.org/10.1002/cam4.820

Ejemplares similares

Pulmonary Metastases After Low-Dose-Rate Brachytherapy for Localized Prostate Cancer
por: Kido, Masahito, et al.
Publicado: (2014)

Transperineal prostate brachytherapy, using I-125 seed with or without adjuvant androgen deprivation, in patients with intermediate-risk prostate cancer: study protocol for a phase III, multicenter, randomized, controlled trial
por: Miki, Kenta, et al.
Publicado: (2010)

A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer
por: Miki, Kenta, et al.
Publicado: (2016)

Analysis of prognostic factors in localized high-risk prostate cancer patients treated with HDR brachytherapy, hypofractionated 3D-CRT and neoadjuvant/adjuvant androgen deprivation therapy (trimodality therapy)
por: Aoki, Manabu, et al.
Publicado: (2014)

Trimodal therapy with high-dose-rate brachytherapy and hypofractionated external beam radiation combined with long-term androgen deprivation for unfavorable-risk prostate cancer
por: Mori, Keiichiro, et al.
Publicado: (2021)

Dose gradient impact on equivalent dose at 2 Gy for high dose rate interstitial brachytherapy
por: Hannoun-Levi, Jean-Michel, et al.
Publicado: (2012)

Hyperfractionation of HDR brachytherapy – influence on doses and biologically equivalent doses in clinical target volume and healthy tissues
por: Skowronek, Janusz, et al.
Publicado: (2009)

Can we avoid dose escalation for intermediate-risk prostate cancer in the setting of short-course neoadjuvant androgen deprivation?
por: Shakespeare, Thomas P, et al.
Publicado: (2016)

Dose escalation using ultra-high dose IMRT in intermediate risk prostate cancer without androgen deprivation therapy: preliminary results of toxicity and biochemical control
por: Petrongari, Maria Grazia, et al.
Publicado: (2013)

The role of androgen deprivation therapy on biochemical failure and distant metastasis in intermediate-risk prostate cancer: effects of radiation dose escalation
por: Ludwig, Michelle S, et al.
Publicado: (2015)

Dose equivalent
por: International Commission on Radiation Units and Measurements. Bethesda
Publicado: (1973)

Equivalence of Gyn GEC-ESTRO guidelines for image guided cervical brachytherapy with EUD-based dose prescription
por: Shaw, William, et al.
Publicado: (2013)

Focal low-dose-rate prostate brachytherapy for low- and intermediate-risk prostate cancer
por: Kunogi, Hiroaki, et al.
Publicado: (2020)

Comparative effectiveness of low-dose-rate brachytherapy with or without external beam radiotherapy in favorable and unfavorable intermediate-risk prostate cancer
por: Tsumura, Hideyasu, et al.
Publicado: (2022)

Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
por: Amit, Uri, et al.
Publicado: (2019)

Clinical outcomes of low-dose-rate brachytherapy based radiotherapy for intermediate risk prostate cancer
por: Okamoto, Keisei, et al.
Publicado: (2020)

The contributions of intermediate energy neutrons to the dose rate equivalent outside the shielding of high energy accelerators
por: Nachtigall, D
Publicado: (1966)

Patients’ Preferences for Androgen Deprivation Therapy in the Treatment of Intermediate-Risk Prostate Cancer
por: De, Brian, et al.
Publicado: (2022)

Long-term outcomes from dose-escalated image-guided intensity-modulated radiotherapy with androgen deprivation: encouraging results for intermediate- and high-risk prostate cancer
por: Wilcox, Shea W, et al.
Publicado: (2014)

Long-term outcomes of dose-escalated intensity modulated radiation therapy alone without androgen deprivation therapy for patients with intermediate and high-risk prostate cancer
por: Gadia, Rafael, et al.
Publicado: (2016)

Oncologic Outcomes of Radical Prostatectomy and High-Dose Intensity-Modulated Radiotherapy with Androgen-Deprivation Therapy for Relatively Young Patients with Unfavorable Intermediate-Risk Prostate Adenocarcinoma
por: Wu, Szu-Yuan, et al.
Publicado: (2021)

Influence of length of interval between pulses in PDR brachytherapy (PDRBT) on value of Biologically Equivalent Dose (BED) in healthy tissues
por: Skowronek, Janusz, et al.
Publicado: (2010)

Long-term biochemical progression-free survival following brachytherapy for prostate cancer: Further insight into the role of short-term androgen deprivation and intermediate risk group subclassification
por: Matzkin, Haim, et al.
Publicado: (2019)

Ten‐step method of high‐dose LDR (125)I brachytherapy for intermediate‐risk prostate cancer
por: Okamoto, Keisei
Publicado: (2021)

Direct comparison of low-dose-rate brachytherapy versus radical prostatectomy using the surgical definition of biochemical recurrence for patients with intermediate-risk prostate cancer
por: Tsumura, Hideyasu, et al.
Publicado: (2022)

AB37. The combination of I brachytherapy with intermittent androgen deprivation in treating locally advanced prostate cancer
por: Huang, Yi
Publicado: (2014)

Need of independent dose verification in brachytherapy
por: Shanta, A
Publicado: (2008)

Low dose rate prostate brachytherapy
por: Stish, Bradley J., et al.
Publicado: (2018)

An automated dose verification software for brachytherapy
por: Wang, Xianliang, et al.
Publicado: (2018)

Prostate-specific antigen kinetics and metastasis-free survival in patients treated with external beam radiotherapy combined with high-dose-rate brachytherapy boost and androgen deprivation therapy for localized prostate cancer
por: Miszczyk, Marcin, et al.
Publicado: (2022)

Focal low dose-rate brachytherapy for low to intermediate risk prostate cancer: preliminary experience at an Australian institution
por: Anderson, Elliot, et al.
Publicado: (2021)

Definitions of “Cure” After Low-Dose-Rate Brachytherapy in Low- and Intermediate-Risk Prostate Cancer: Phoenix or Surgical?
por: Boehle, Andreas, et al.
Publicado: (2022)

Conceptual basis for the determination of dose equivalent
por: International Commission on Radiation Units and Measurements. Bethesda
Publicado: (1976)

Biological dose summation of intensity-modulated arc therapy and image-guided high-dose-rate interstitial brachytherapy in intermediate- and high-risk prostate cancer
por: Fröhlich, Georgina, et al.
Publicado: (2020)

Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy
por: Cagney, Daniel N., et al.
Publicado: (2017)

Combined brachytherapy and external beam radiotherapy without adjuvant androgen deprivation therapy for high-risk prostate cancer
por: Ohashi, Toshio, et al.
Publicado: (2014)

Brachytherapy for cervix cancer: low-dose rate or high-dose rate brachytherapy – a meta-analysis of clinical trials
por: Viani, Gustavo A, et al.
Publicado: (2009)

Impact of pre-brachytherapy magnetic resonance imaging on dose-volume histogram of locally advanced cervical cancer patients treated with radiotherapy including high-dose-rate brachytherapy
por: Murofushi, Keiko Nemoto, et al.
Publicado: (2021)

Predictive value of Excel forms based on an automatic calculation of dose equivalent in 2 Gy per fraction in adaptive brachytherapy for cervical cancer
por: Cheng, Guanghui, et al.
Publicado: (2020)

Prevention of high-dose-rate brachytherapy accidents
por: Commission Internationale de Protection contre les Radiations
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_n4h5l8a68g6mv873aaq02rghvl